Published in Am J Clin Oncol on December 01, 2005
Ten-year survival after liver resection for colorectal metastases: systematic review and meta-analysis. ISRN Oncol (2011) 0.99
Adjuvant radioimmunotherapy trial with iodine-131-labeled anti-carcinoembryonic antigen monoclonal antibody F6 F(ab')2 after resection of liver metastases from colorectal cancer. Clin Cancer Res (2008) 0.81
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol (2007) 25.52
A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature (2006) 24.52
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med (2003) 12.17
Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24. Nat Genet (2007) 9.88
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature (2012) 8.31
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol (2008) 7.89
Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA (2011) 7.10
Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med (2013) 7.00
Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer. Nat Genet (2008) 6.97
Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol (2010) 6.87
Genome-wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21. Nat Genet (2008) 6.75
Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA (2010) 6.65
Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet (2009) 5.14
Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science (2012) 4.92
A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet (2010) 4.89
Cell death. N Engl J Med (2009) 4.75
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum (2002) 4.69
Discovery of cross-reactive probes and polymorphic CpGs in the Illumina Infinium HumanMethylation450 microarray. Epigenetics (2013) 4.61
Reversal of the TCR stop signal by CTLA-4. Science (2006) 4.59
Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst (2009) 4.36
Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA (2006) 4.34
Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period. Arthritis Rheum (2002) 4.23
DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst (2011) 4.08
Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol (2013) 4.04
Tumour heterogeneity in the clinic. Nature (2013) 3.92
Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. J Clin Oncol (2013) 3.76
Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet (2012) 3.69
Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol (2004) 3.67
Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA (2007) 3.62
Predictors of infection in rheumatoid arthritis. Arthritis Rheum (2002) 3.47
The statins as anticancer agents. Clin Cancer Res (2003) 3.36
Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. J Clin Oncol (2005) 3.34
Impact and perceptions of mandatory tumor biopsies for correlative studies in clinical trials of novel anticancer agents. J Clin Oncol (2006) 3.31
ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov (2011) 3.27
Mechanisms of cardiac and renal dysfunction in patients dying of sepsis. Am J Respir Crit Care Med (2013) 3.25
Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk. Nat Genet (2012) 3.19
Completion of therapy by Medicare patients with stage III colon cancer. J Natl Cancer Inst (2006) 3.18
Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol (2007) 3.16
Measured and estimated GFR in healthy potential kidney donors. Am J Kidney Dis (2004) 3.11
Risks of colorectal and other cancers after endometrial cancer for women with Lynch syndrome. J Natl Cancer Inst (2013) 3.06
Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors. J Am Coll Surg (2004) 2.97
Germ-line DNA copy number variation frequencies in a large North American population. Hum Genet (2007) 2.94
EphB receptor activity suppresses colorectal cancer progression. Nature (2005) 2.84
Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. J Clin Oncol (2005) 2.83
Identification of Lynch syndrome among patients with colorectal cancer. JAMA (2012) 2.77
Association between biallelic and monoallelic germline MYH gene mutations and colorectal cancer risk. J Natl Cancer Inst (2004) 2.68
Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol (2011) 2.57
Quality of reporting of modern randomized controlled trials in medical oncology: a systematic review. J Natl Cancer Inst (2012) 2.57
Identification of Genetic Susceptibility Loci for Colorectal Tumors in a Genome-Wide Meta-analysis. Gastroenterology (2012) 2.57
CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome Res (2013) 2.57
Medication reconciliation at hospital discharge: evaluating discrepancies. Ann Pharmacother (2008) 2.57
Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol (2005) 2.52
Prevalence of alterations in DNA mismatch repair genes in patients with young-onset colorectal cancer. Clin Gastroenterol Hepatol (2010) 2.50
Multiple common susceptibility variants near BMP pathway loci GREM1, BMP4, and BMP2 explain part of the missing heritability of colorectal cancer. PLoS Genet (2011) 2.47
Assumptions of expected benefits in randomized phase III trials evaluating systemic treatments for cancer. J Natl Cancer Inst (2012) 2.46
Impact of wait times on survival for women with uterine cancer. J Clin Oncol (2013) 2.45
Risks of primary extracolonic cancers following colorectal cancer in lynch syndrome. J Natl Cancer Inst (2012) 2.44
Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population-based study. Gastroenterology (2007) 2.39
Surgical resection of hepatic and pulmonary metastases from colorectal carcinoma. J Am Coll Surg (2006) 2.37
Meta-analysis of new genome-wide association studies of colorectal cancer risk. Hum Genet (2011) 2.35
Metachronous colorectal cancer risk for mismatch repair gene mutation carriers: the advantage of more extensive colon surgery. Gut (2010) 2.30
Bile duct injuries associated with laparoscopic cholecystectomy: timing of repair and long-term outcomes. Arch Surg (2010) 2.26
Depletion of dendritic cells, but not macrophages, in patients with sepsis. J Immunol (2002) 2.25
Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes. Surgery (2006) 2.24
Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. J Clin Oncol (2012) 2.22
Distinguishing right from left colon by the pattern of gene expression. Cancer Epidemiol Biomarkers Prev (2003) 2.22
Overexpression of Bcl-2 in the intestinal epithelium improves survival in septic mice. Crit Care Med (2002) 2.20
Fatal Kaposi's sarcoma-associated immune reconstitution following HAART initiation. Int J STD AIDS (2005) 2.19
Molecular characterization of MSI-H colorectal cancer by MLHI promoter methylation, immunohistochemistry, and mismatch repair germline mutation screening. Cancer Epidemiol Biomarkers Prev (2008) 2.12
SARS among critical care nurses, Toronto. Emerg Infect Dis (2004) 2.10
Explaining black-white differences in receipt of recommended colon cancer treatment. J Natl Cancer Inst (2005) 2.08
Analysis of the gene coding for the BRCA2-interacting protein PALB2 in familial and sporadic pancreatic cancer. Gastroenterology (2009) 2.08
Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations. Am J Clin Pathol (2003) 2.07
Pancreatic cancer genetic epidemiology consortium. Cancer Epidemiol Biomarkers Prev (2006) 2.04
Nasopharyngeal carcinoma: the next challenges. Eur J Cancer (2010) 2.04
The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev (2007) 2.03
Survival after hepatic resection for colorectal metastases: a 10-year experience. Ann Surg Oncol (2006) 2.02
Variants on 9p24 and 8q24 are associated with risk of colorectal cancer: results from the Colon Cancer Family Registry. Cancer Res (2007) 2.02
Randomized phase II trials: inevitable or inadvisable? J Clin Oncol (2010) 2.02
Case-control study of overweight, obesity, and colorectal cancer risk, overall and by tumor microsatellite instability status. J Natl Cancer Inst (2010) 1.99
Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway. J Clin Oncol (2012) 1.95
MLH1 germline epimutations as a factor in hereditary nonpolyposis colorectal cancer. Gastroenterology (2005) 1.94
Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clin Cancer Res (2010) 1.93
A novel mesh processing based technique for 3D plant analysis. BMC Plant Biol (2012) 1.91
Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol (2007) 1.91
The PREMM(1,2,6) model predicts risk of MLH1, MSH2, and MSH6 germline mutations based on cancer history. Gastroenterology (2010) 1.88
Menstrual and reproductive risk factors and risk for gastric adenocarcinoma in women: findings from the canadian national enhanced cancer surveillance system. Ann Epidemiol (2006) 1.88
Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. Clin Cancer Res (2003) 1.82
YeastHub: a semantic web use case for integrating data in the life sciences domain. Bioinformatics (2005) 1.82
Transcriptional cooperation between the transforming growth factor-beta and Wnt pathways in mammary and intestinal tumorigenesis. Cancer Res (2007) 1.81
Designing transformative clinical trials in the cancer genome era. J Clin Oncol (2013) 1.79
The maize methylome influences mRNA splice sites and reveals widespread paramutation-like switches guided by small RNA. Genome Res (2013) 1.78
Sepsis induces apoptosis and profound depletion of splenic interdigitating and follicular dendritic cells. J Immunol (2003) 1.76
An aggressive surgical approach leads to improved survival in patients with gallbladder cancer: a 12-year study at a North American Center. Ann Surg (2005) 1.76